Novartis hid manipulated data about its $2 million gene therapy Zolgensma from the FDA; US District Judge Kristine Baker granted a preliminary injunction preventing Arkansas from enforcing 3 abortion restrictions; a federal judge in Ohio expressed support for a plan by attorneys representing cities and counties suing US opioid manufacturers and distributors that would bring every US community into their settlement talks despite objections from most states.
Novartis hid manipulated data about its $2 million gene therapy Zolgensma from the FDA, the agency reported. The concealment occurred while the company was applying for approval for the treatment for spinal muscular atrophy, then delayed reporting the issue, the agency said. The inaccurate data involved testing in mice of 2 different strengths of the treatment and did not affect the safety or efficacy of the treatment, but had the agency known about the issue, it would have delayed approval.
US District Judge Kristine Baker granted a preliminary injunction preventing Arkansas from enforcing 3 abortion restrictions, The Associated Press reported. They include a measure prohibiting abortion at 18 weeks, a requirement that physicians performing abortions be board-certified or board-eligible in obstetrics and gynecology, and the third prohibits doctors from performing an abortion if it’s being sought because the fetus was diagnosed with Down syndrome.
A federal judge in Ohio expressed support for a plan by attorneys representing cities and counties suing US opioid manufacturers and distributors that would bring every community nationally into their settlement talks despite objections from most states. US District Judge Dan Polster said the idea could allow the defendants accused of fueling the opioid crisis in nearly 2000 lawsuits before him the ability to obtain “global peace.” Reuters said the proposal calls for creating a class of up to 3000 counties and 30,000 municipalities that could vote on whether to accept any settlement the plaintiffs reach with defendants. Bloomberg reported that 3 of the companies—McKesson, Cardinal Health, and AmerisourceBergen—have offered $10 billion to settle claims; the National Association of Attorneys General, on behalf of 35 states, want $45 billion.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen